AMPE Key Statistics, Chart & Performance
The current stock price of AMPE is 0.62 USD. In the past month the price decreased by -62.2%. In the past year, price decreased by -84.61%.
AMPE Latest News, Press Relases and Analysis
AMPE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.22 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 499.88B | ||
| MRK | MERCK & CO. INC. | 11.88 | 261.34B | ||
| PFE | PFIZER INC | 8.03 | 146.18B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.51 | 100.25B | ||
| ZTS | ZOETIS INC | 20.14 | 56.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 23.23B | ||
| VTRS | VIATRIS INC | 4.57 | 12.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.28 | 11.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.68 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.52B |
Related stock screener links
About AMPE
Company Profile
Ampio Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Englewood, Colorado and currently employs 8 full-time employees. The company went IPO on 2011-05-19. Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The firm is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
Company Info
AMPIO PHARMACEUTICALS INC
9800 Mount Pyramid Court, Suite 400
Englewood COLORADO 80112 US
CEO: Michael Macaluso
Employees: 8
Phone: 17204376500
AMPIO PHARMACEUTICALS INC / AMPE FAQ
What does AMPIO PHARMACEUTICALS INC do?
Ampio Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Englewood, Colorado and currently employs 8 full-time employees. The company went IPO on 2011-05-19. Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The firm is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
Can you provide the latest stock price for AMPIO PHARMACEUTICALS INC?
The current stock price of AMPE is 0.62 USD. The price decreased by -12.91% in the last trading session.
What is the dividend status of AMPIO PHARMACEUTICALS INC?
AMPE does not pay a dividend.
How is the ChartMill rating for AMPIO PHARMACEUTICALS INC?
AMPE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of AMPIO PHARMACEUTICALS INC (AMPE)?
AMPIO PHARMACEUTICALS INC (AMPE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.13).
Can you provide the upcoming earnings date for AMPIO PHARMACEUTICALS INC?
AMPIO PHARMACEUTICALS INC (AMPE) will report earnings on 2024-05-06, after the market close.
Who owns AMPIO PHARMACEUTICALS INC?
You can find the ownership structure of AMPIO PHARMACEUTICALS INC (AMPE) on the Ownership tab.
AMPE Technical Analysis
AMPE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AMPE. AMPE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AMPE Financial Highlights
Over the last trailing twelve months AMPE reported a non-GAAP Earnings per Share(EPS) of -11.13. The EPS increased by 48.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -150.51% | ||
| ROE | -256.93% | ||
| Debt/Equity | 0 |
AMPE Forecast & Estimates
6 analysts have analysed AMPE and the average price target is 2.04 USD. This implies a price increase of 229.03% is expected in the next year compared to the current price of 0.62.